Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas

Blood

Volumn 89, Issue 2, 1997, Pages 601-609

  Wilson, Wyndham H ^a   Teruya Feldstein, Julie ^a   Fest, Thierry ^a   Harris, Cynthia ^a   Steinberg, Seth M ^a   Jaffe, Elaine S ^a   Raffeld, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY KI 67; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0031018994     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.2.601     Document Type: Article

References (37)

1. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776, 1993
2. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
3. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S: Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell lymphoma: An analysis of 83 cases. J Clin Oncol 12:149, 1994
4. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701, 1992
5. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutations is associated with progression in follicular lymphomas. Blood 82:1994, 1993
6. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853, 1993
7. Kohn KW, Jackman J, O'Connor PM: Cell cycle control and cancer chemotherapy. J Cellular Biochem 54:440, 1994
8. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphomas. Blood 87:265, 1996
9. Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337, 1994
10. Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D, Kluin PM: Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population based study. J Clin Oncol 14:2131, 1996
11. Hill ME, MacLennan KA, Cunningham DC, Vaughan-Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan-Hudson G, Mason D, Selby P, Linch DC: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British national lymphoma investigation study. Blood 88:1046, 1996
12. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11:14)(q13;q32). Blood 86:2892, 1995
13. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440, 1988
14. Green DR, Bissonnette RP, Cotter TG: Apoptosis and cancer. Princ Pract Oncol Updates 8:1, 1994
15. Hug V, Johnston D, Finders M, Hortobagyi G: Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46:147, 1986
16. Lee WP: The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. Cancer Lett 73:105, 1993
17. Valeriote F, van Putten L: Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res 35:2619, 1975
18. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfeld AG: The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154:223, 1988
19. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460, 1994
20. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphomas. J Clin Oncol 11:1573, 1993
21. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC: A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. Hum Genet 91:25, 1993
22. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r X c contingency tables. J Am Stat Assoc 78:427, 1983
23. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
24. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
25. Cox D: Regression models and life tables. J Royal Stat Soc 34:187, 1972
26. Mathews DE, Farewell VT (eds): Using and Understanding Medical Statistics. Basel, Switzerland, Karger, 1985, p 148
27. Press SJ, Wilson S: Choosing between logistic regression and discriminant analysis. J Am Stat Assoc 73:699, 1978
28. Shipp MA: The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
29. The non-Hodgkin's lymphomas pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
30. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
31. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M: P-53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351, 1996
32. Grierson HL, Wooldridge TN, Hess M, Ratashak A et al: Proliferative fraction and DNA content are lower in B-cell non-Hodgkin's lymphomas with the t(14; 18). Leuk Lymphoma 19:253, 1995
33. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13:1995, 1995
34. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, Lee JS, Otsuki T, Stetler-Stevenson M, Jaffe ES, Solomon D, Wilson WH, Fojo A, Bates SE: Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay. Blood 86:1515, 1995
35. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerization in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
36. Leocini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H: Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 142:755, 1993
37. Yuen AR, Kamel OW, Halpern J, Horning SJ: Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726, 1995